Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis.

Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KH.

J Hematol Oncol. 2015 Jun 24;8:74. doi: 10.1186/s13045-015-0172-y.

2.

Extramedullary Waldenström macroglobulinemia.

Banwait R, Aljawai Y, Cappuccio J, McDiarmid S, Morgan EA, Leblebjian H, Roccaro AM, Laubach J, Castillo JJ, Paba-Prada C, Treon S, Redd R, Weller E, Ghobrial IM.

Am J Hematol. 2015 Feb;90(2):100-4. doi: 10.1002/ajh.23880. Epub 2014 Nov 19.

3.

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, Shurafa M, Kyle RA, Crowley JJ, Barlogie B.

Blood. 2001 Jul 1;98(1):41-8.

4.

Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia.

Yi S, Cui R, Li Z, An G, Qi J, Zou D, Zhang P, Chen H, Wang J, Chang H, Qiu L.

Chin Med J (Engl). 2014;127(12):2327-31.

PMID:
24931251
5.

Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.

Dimopoulos MA, Hamilos G, Zervas K, Symeonidis A, Kouvatseas G, Roussou P, Gika D, Karmiris T, Bourantas K, Zomas A, Mitsouli C, Xilouri I, Vervessou E, Matsis K, Anagnostopoulos N, Economopoulos T; Greek Myeloma Study Group.

Ann Oncol. 2003 Aug;14(8):1299-305.

PMID:
12881396
6.

Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.

Saito A, Isoda A, Kojima M, Yokohama A, Tsukune Y, Sasaki M, Ito S, Ohtsu A, Koike M, Murayama K, Moriya K, Tamura H, Matsumoto M, Nakahashi H, Tanosaki S, Sakura T, Kawamura T, Miyanaga T, Nakamura N, Murakami H, Handa H, Tsukamoto N.

Int J Hematol. 2017 Nov;106(5):681-690. doi: 10.1007/s12185-017-2297-y. Epub 2017 Jul 7.

PMID:
28687991
7.

Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.

Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG.

J Clin Oncol. 2013 Jan 20;31(3):301-7. doi: 10.1200/JCO.2012.44.7920. Epub 2012 Dec 10.

PMID:
23233721
8.

Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study.

Björkholm M, Johansson E, Papamichael D, Celsing F, Matthews J, Lister TA, Rohatiner AZ.

Semin Oncol. 2003 Apr;30(2):226-30.

PMID:
12720141
9.

Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.

Kristinsson SY, Eloranta S, Dickman PW, Andersson TM, Turesson I, Landgren O, Björkholm M.

Am J Hematol. 2013 Jan;88(1):60-5. doi: 10.1002/ajh.23351. Epub 2012 Nov 19.

10.

Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients.

Lin P, Bueso-Ramos C, Wilson CS, Mansoor A, Medeiros LJ.

Am J Surg Pathol. 2003 Aug;27(8):1104-13.

PMID:
12883242
11.

[Clinical features of 16 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia].

Wang JJ, Jing HM, Shen HW, Xu JS, Li M, Gao ZF, Ke XY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Dec;18(6):1494-8. Chinese.

PMID:
21176358
12.

Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.

Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, Wolf RC, Hoffmann RJ, Lust JA, Witzig TE, Lacy MQ, Dispenzieri A, Vincent Rajkumar S, Zeldenrust SR, Greipp PR, Kyle RA.

Br J Haematol. 2006 Apr;133(2):158-64.

PMID:
16611306
13.

Waldenström macroglobulinemia.

Vijay A, Gertz MA.

Blood. 2007 Jun 15;109(12):5096-103. Epub 2007 Feb 15. Review.

14.

Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.

Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette ZY, Orlowski RZ, Young KH.

Leuk Lymphoma. 2016 May;57(5):1104-13. doi: 10.3109/10428194.2015.1096357. Epub 2015 Dec 23.

PMID:
26421453
15.

High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W, Kolbe K, Gorin NC, Thomson K, Milpied N, Niederwieser D, Indrák K, Corradini P, Sureda A, Schmitz N.

J Clin Oncol. 2010 May 1;28(13):2227-32. doi: 10.1200/JCO.2009.24.4905. Epub 2010 Apr 5.

PMID:
20368570
16.

Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases.

Facon T, Brouillard M, Duhamel A, Morel P, Simon M, Jouet JP, Bauters F, Fenaux P.

J Clin Oncol. 1993 Aug;11(8):1553-8.

PMID:
8336194
17.

Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases.

García-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A, Rodríguez-García JA, Massó P, Pérez-Aliaga A, Monteagudo MD, Navarro I, Moreno G, Toledo C, Alonso A, Besses C, Besalduch J, Jarque I, Salama P, Rivas JA, Navarro B, Bladé J, Miguel JF; Spanish Group for the Study of Waldenström Macroglobulinaemia and PETHEMA (Programme for the Study and Treatment of Haematological Malignancies).

Br J Haematol. 2001 Dec;115(3):575-82. Review.

PMID:
11736938
18.

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.

Treon SP, Yang G, Hanzis C, Ioakimidis L, Verselis SJ, Fox EA, Xu L, Hunter ZR, Tseng H, Manning RJ, Patterson CJ, Sheehy P, Turnbull B.

Br J Haematol. 2011 Jul;154(2):223-8. doi: 10.1111/j.1365-2141.2011.08726.x. Epub 2011 May 12.

PMID:
21564078
19.

Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.

Treon SP, Tripsas C, Hanzis C, Ioakimidis L, Patterson CJ, Manning RJ, Sheehy P, Turnbull B, Hunter ZR.

Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):433-7. doi: 10.1016/j.clml.2012.08.006. Epub 2012 Oct 17.

PMID:
23084402
20.

Waldenstrom macroglobulinemia: prognosis and management.

Oza A, Rajkumar SV.

Blood Cancer J. 2015 Mar 27;5:e394. doi: 10.1038/bcj.2015.28. Review. Erratum in: Blood Cancer J. 2016;6:e391.

Supplemental Content

Support Center